|
On Tuesday, the Food and Drug Administration filed a
permanent injunction against Terumo Cardiovascular Systems' sale of heart-lung
bypass systems. These devices, which circulate blood during chest surgeries,
were barred by the FDA after inspectors discovered more than a dozen quality
control issues at the company's manufacturing plant in Ann Arbor, Michigan last
march.
The quality control issues centered on Terumo's procedures
for dealing with defective devices, customer complaints, and product design.
Similar issues were cited by the FDA in 2004 and 2006.
While Terumo has been barred from making new sales, ABC news
reports that the FDA is not recalling the products from the market due to
concerns about a shortage of machines. Additionally, the agency is permitting
the company to service and replace existing machines.
Terumo will pay $35 million in back profits from the
devices, with additional fees lingering if they do not comply to the government's
satisfaction.
Do you think the company is receiving proper repercussions
for overlooking quality control?
Source: ABC News
|